OTCM
CGPHF
Market cap2.04bUSD
, Last price
USD
Name
Grand Pharmaceutical Group Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
Related entities
Subsidiaries
GRAND DECADE DEVELOPMENTS LIMITED
Key people
Xiaofeng Shi
Chairman of the Board of Grand Pharma, China
Chit Yee Lam
Executive Director · since 2024
Weikun Tang
Executive Chairman of the Board; President of Grand Pharma, China · since 2021
Guang Yang
Executive Director · since 2023
Chao Zhou
Executive Director · since 2023
Company Secretary · since 2011
Independent Non-Executive Director · since 2018
Geng Pei
Independent Non-Executive Director · since 2011
Tosi Wan So
Independent Non-Executive Director · since 2005
Li Na Xing
Non-Executive Independent Director · since 2024
Legal address
Clarendon House, 2 Church Street
Hamilton HM 11
BM
Hamilton HM 11
BM
Headquarters
Units 3302, The Center, 99 Queen’s Road Central
Hong Kong 999077
HK
Hong Kong 999077
HK
Previous name
China Apollo Holdings Limited
Previous name
MAXX Bioscience Holdings Limited
Previous name
China Grand Pharmaceutical and Healthcare Holdings Limited
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||